welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Cardiac Magnetic Resonance in Children With Muscular Dystrophy
study id #: NCT01081080
condition: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
This protocol will exploit novel state of the art cardiovascular magnetic resonance techniques to examine important changes in the heart in children with muscular dystrophy. The purpose of this study is to compare cardiac magnetic resonance (CMR) with the collected cardiac outcome data obtained in protocol: PITT1109 – Cardiac Outcome Measures in Children with Muscular Dystrophy.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: April 2010
estimated completion: October 2011
size / enrollment: 20
Participant enrolled in the CINRG study: PITT1109 - Cardiac Outcome Measures in Children with Muscular Dystrophy
• Pregnant woman (when uncertain, participants will undergo urine testing) or lactating women
• Decompensated congestive heart failure (unable to lie flat during CMR)
• Impaired renal excretory function (calculated Glomerular Filtration Rate less than 30mL/min)
• Contra-indications to Magnetic Resonance Imaging:
-Cardiac pacemaker or implantable defibrillator
-Cerebral aneurysm clip
-Metallic ocular foreign body
-Any implanted device (i.e. insulin pump, drug infusion device)
-Metal shrapnel or bullet
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access programSince the 1970s, the FDA has helped to f...
Virtual Reality in Individuals With Duchenne Muscular DystrophyWith the growing accessibility of comput...
Outcome Measures in Duchenne Muscular Dystrophy: A Natural History StudyNovel emerging therapies for Duchenne Mu...
Sarepta Receives Negative CHMP Re-examination Opinion for EteplirsenSarepta Therapeutics, Inc., a commercial...
For Many Boys With Duchenne Muscular Dystrophy, Bright Hope Lies Just Beyond ReachLucas was 5 before his parents, Bill and...
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...
Association between specific dystrophin gene mutations and myocardial fibrosis by cardiovascular magnetic resonance ...Background Duchenne (DMD) and Becker (B...